Compare Johnson Controls International PLC (JCI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Organon & Co. Common Stock — how do they compare? Johnson Controls International PLC trades at $151.51 (market cap $92.34B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Johnson Controls International PLC is far larger — about 25.6× Organon & Co. Common Stock's market cap, and Johnson Controls International PLC pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 66 Days and Organon & Co. Common Stock for 0 Days on average.
| JCI | OGN | |
|---|---|---|
Market Cap | $92.34B | $3.61B |
Volume | 5,497,477 | 1,808,049 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $13.81 |
52-Week Low | $108.54 | $5.70 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $101.17B | $11.03B |
Dividend Yield | 1.05% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $156.47, up 0.68% today, with a bullish technical outlook and strong institutional support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.58. Revenue for 2025 was $23.60B, with net income surging to $3.29B, reflecting a robust profit margin of 13.94%. Recent news highlights strong Q3 2026 results and raised full-year guidance, driven by demand in data-center thermal management systems.
JCI presents a favorable investment case with solid fundamentals, analyst consensus pointing to a $172.50 price target, and no sell ratings among 45 analysts. Key risks include rising debt-to-asset ratios and macroeconomic sensitivity. The stock's valuation multiples are elevated, but growth in high-margin segments supports upside potential. Institutional ownership trends show increased positions, reinforcing confidence in the company's strategic direction.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
